SCHEMBL2565000

SCHEMBL2565000

Cc1[nH]n(-c2ccc(S(=O)(=O)N3CCCCCC3)cn2)c(=O)c1Cc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.57
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ L3MBTL1 Q9Y468 5/20 0.49
▸ NOX4 Q9NPH5 1/20 0.46
▸ GAA P10253 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ TSHR P16473 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ ALKBH3 Q96Q83 2/20 0.44
▸ KAT8 Q9H7Z6 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ MCOLN3 Q8TDD5 1/20 0.43
▸ NLRP3 Q96P20 1/20 0.43
▸ POLB P06746 2/20 0.42
▸ MAPT P10636 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15258785 0.99 KDM4E (0.58) KDM4EMEN1KMT2AL3MBTL1NOX4
SCHEMBL15258757 0.90 L3MBTL1 (0.49) KDM4EMEN1KMT2AL3MBTL1NOX4
SCHEMBL2568176 0.90 KDM4E (0.55) KDM4EMEN1KMT2AL3MBTL1NOX4
SCHEMBL15643049 0.90 KDM4E (0.49) KDM4EMEN1KMT2AL3MBTL1NOX4
Hydrochloric Acid SCHEMBL15258808 0.89 KDM4E (0.48) KDM4EMEN1KMT2AL3MBTL1NOX4
SCHEMBL15258870 0.88 KMT2A (0.45) KDM4EMEN1KMT2AL3MBTL1NOX4
SCHEMBL15258732 0.87 SMN1; SMN2 (0.54) KDM4EMEN1KMT2AL3MBTL1NOX4
SCHEMBL15258733 0.83 GAA (0.47) KDM4EMEN1KMT2AL3MBTL1NOX4
SCHEMBL15258875 0.82 LMNA (0.50) KDM4EMEN1KMT2ANOX4GAA
SCHEMBL15258753 0.82 NOX4 (0.45) KDM4EMEN1KMT2AL3MBTL1NOX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2382205-B1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI SA (FR) 2014-04-23 — — EP claimed
US-20110294788-A1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI (FR) 2011-12-01 — — US claimed
EP-2382205-B1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI SA (FR) 2014-04-23 — — EP disclosed
US-8541455-B2 Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof as HIF activators SANOFI (FR) 2013-09-24 — — US disclosed
US-20110294788-A1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI (FR) 2011-12-01 — — US disclosed
EP-2382205-A2 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI (FR) 2011-11-02 — — EP disclosed
WO-2010076524-A2 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI-AVENTIS (FR) 2010-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294788-A1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS HIF1AN, HIF1A, EGLN2 KDM4E 1006/4885MEN1 3807/4885KMT2A 1060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback